Chemence Medical has secured approval from the US Food and Drug Administration (FDA) for its Exofin precision pen for wound closure.
The new medical device is part of the company’s Exofin products, which are claimed to be the fast drying 2octyl cyanoacrylate topical adhesives with a high viscosity formulation.
Chemence Medical president Jeff Roberson said: “Doctors and surgeons emphasized they wanted an adhesive that could be applied with precision, regardless of the wound size or location, even in the most delicate procedures.
“We designed the Exofin Precision Pen to meet these needs by making it natural to hold, incorporating multiple applicators, and allowing doctors to vary the flow of adhesive with a pressure-controlled delivery system and higher viscosity formulation while maintaining the fast dry times of our other Exofin products.”
The Exofin precision pen is said to be the only pen-style applicator on the market with an adjustable tip to help the user to control the adhesive width by supporting three different application methods in a single device.
The application methods include a micro-bristle brush for wide coverage, an inverted brush for narrow lines, and an angle precision tip for micro lines.
It also features an ergonomic design with a grooved non-slip surface and a pressure-controlled variable adhesive flow rate, as well as consists of up to 152% more usable adhesive than other products in the industry.
The pen, which offers a 14-day microbial barrier to enhance recovery, enable patients to resume normal activities faster including showering without special coverings or dressings.
Roberson further added: “Whether it’s a substantial abdominal incision, a fine incision behind the ear or somewhere in between, the Exofin Precision Pen is ready to be that versatile tool for physicians to improve patient outcomes.”
